title: [Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group].
abstract: In an attempt to create uniform nationwide guidelines for the management of all stages of endometrial carcinoma, and to limit the use of adjuvant radiation therapy in stage I disease to high-risk patients only, a protocol was developed by the Danish Endometrial Cancer group (DEMCA). From September 1986 through August 1988, 1214 women in Denmark with newly diagnosed carcinoma of the endometrium have been treated according to this protocol. This figure represents all endometrial carcinomas diagnosed in Denmark during this two-year period. The primary treatment was total abdominal hysterectomy and bilateral salpingo-oophorectomy, no preoperative radiation therapy was delivered. In 1039 cases no macroscopic residual tumour and/or microscopic tumor tissue in the resection margins was found following surgery. Based on surgery and histopathology, these patients were classified as: P-stage I low risk (n = 641), P-stage I high risk (n = 235), P-stage II (n = 105) and P-stage III, Group 1 (n = 58). No postoperative radiation therapy was given to P-I low risk cases. P-I high risk, P-II, and P-III (Group 1) cases received external radiation therapy. Recurrence rate at 68-92 months follow-up was 45/641 (7%) in P-I low risk, 36/235 (15%) in P-I high risk, 30/105 (29%) in P-II, and 27/58 (47%) in P-III (Group 1) cases. Fifteen of 17 vaginal recurrences in P-I low risk cases were salvaged (mean observation time 61 months). In this population-based investigation it has been shown that P-stage low-risk patients are adequately treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, and that no pre- or postoperative radiation therapy is necessary.
authors.affiliation: Odense Universitetshospital, Den danske endometriecancergruppe (DEMCA).
authors.forename: H K
authors.initials: HK
authors.lastname: Poulsen
authors.forename: M
authors.initials: M
authors.lastname: Jacobsen
authors.forename: K
authors.initials: K
authors.lastname: Bertelsen
authors.forename: J E
authors.initials: JE
authors.lastname: Andersen
authors.forename: S
authors.initials: S
authors.lastname: Ahrons
authors.forename: J E
authors.initials: JE
authors.lastname: Bock
authors.forename: E
authors.initials: E
authors.lastname: Bostofte
authors.forename: S A
authors.initials: SA
authors.lastname: Engelholm
authors.forename: B
authors.initials: B
authors.lastname: Hølund
authors.forename: A K
authors.initials: AK
authors.lastname: Jakobsen
authors.forename: H
authors.initials: H
authors.lastname: Kiaer
authors.forename: M H
authors.initials: MH
authors.lastname: Nyland
authors.forename: P H
authors.initials: PH
authors.lastname: Pedersen
authors.forename: I S
authors.initials: IS
authors.lastname: Christophersen
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003718:Denmark; D016889:Endometrial Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors